07:20:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2020-09-18 17:11:31
Oslo, Sept 18th 2020 

Dr Per Sontum, founder and employee of the company, has on Sept 18th, 2020 sold
80 645 shares in EXACT Therapeutics AS  at an average price per share of NOK 31
for personal reasons.  Following the transaction, Dr Sontum will control a total
of 1 921 605 shares in EXACT Therapeutics AS, corresponding to 6.4% of the total
outstanding shares and votes.

The transaction is combined with a change in role for Dr Sontum whereby, after a
period of extensive recent sick leave, he temporarily returns to the company to
support key projects leveraging his depth of experience and technical expertise
until April 30, 2021. The Board of EXACT Therapeutics is grateful to Dr Sontum
for his long-standing commitment and leadership that have been instrumental in
bringing Acoustic Cluster Therapy (ACT®) to the clinic as well as his ongoing
support to Dr Rafiq Hasan, CEO of EXACT Therapeutics, until his resignation next
April.

‘I would like to thank Per for his vision and tenacity in driving forward the
ACT platform and look forward to benefitting from his in-depth knowledge and
expertise in his new role’ said Dr Hasan. Dr Sontum said ‘Together with my
co-founders, this has really been a fantastic journey – taking the ACT platform
from an initial idea through to clinical development. I am looking forward to
working with Rafiq and the team over the coming months to ensure a smooth
handover, and I am confident that the company rests in the best of hands for the
future success of ACT.’

Carnegie and the Board of EXACT Therapeutics AS agreed to lift the lock up to
secure an orderly sale of the shares. The remaining shares are subject to the
existing lock-up.

About EXACT EXACT-Tx is a clinical stage Anglo-Norwegian biotech company
developing a technology platform for targeted therapeutic enhancement – Acoustic
Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to
ultrasound-mediated, targeted drug enhancement – with the potential to
significantly amplify the clinical utility of a wide range of therapeutic agents
across a multitude of indications including within oncology (chemotherapy,
immunotherapy), infectious diseases, and neurological conditions. 

www.exact-tx.com

For more information contact: 
Dr Rafiq Hasan, CEO of EXACT-Therapeutics 
Rafiq@exact-tx-com 

Richard Hayhurst/Janet Joy 
Tel +44 7711 821527 
richard@rhapr.eu